Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-IFN-α-2β Combined With NAs in HBV-related HCC After Radical Resection
NCT07553767Phase 1Not yet recruiting
- Sponsor
- Ningbo No. 2 Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2034
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of peginterferon alfa-2b in hepatocellular carcinoma (HCC) and Chronic Hepatitis B (CHB) (2 arms), sponsored by Ningbo No. 2 Hospital. Primary endpoints: Concentration of Hepatitis B Surface Antigen at Week 240, Proportion of patients with HBsAg loss at Week 240 and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatocellular carcinoma (HCC)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07553767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07553767.